Delivering the Future of RNA Medicine Today
Ethris pioneers next-generation mRNA therapeutics and vaccines using its proprietary SNIM®RNA and SNaP LNP® platforms. Our thermostable, multi-route LNP delivery system enables precise, versatile delivery for innovative therapies.
Preparing the Immune System for Viral Threats
Ethris’ primary focus is on the development of first-in-class mRNA-based therapeutics to prevent virus-induced exacerbations in asthma and COPD.
Our lead candidate, ETH47 is a novel mRNA-based therapeutic that activates the body's innate immune defense against respiratory viruses.
In addition, we are utilizing our technology platforms to develop mucosal vaccines and generate protein replacement therapy candidates with an initial focus on rare genetic disorders such as primary ciliary dyskinesia (PCD).
Advancing RNA Delivery Innovation
Ethris’ multi faceted proprietary SNIM® RNA and SNaP LNP® platform technologies enable precise, low-immunogenic multi-cargo delivery, improving treatment outcomes for respiratory and genetic diseases.
Careers
Seizing a once-in-a-lifetime opportunity, reimagining therapeutics in a highly ambitious team
At Ethris, we are proud of our innovative technology and being at the forefront of a new therapeutic modality.
Our diverse, international team combines expertise across multiple disciplines to develop next-generation mRNA therapeutics and vaccines.
Join us as we advance our pipeline through clinical development and scale our next-generation genetic medicines LNP and mRNA platforms.
Partnering
Ethris’ goal is to become the leader in inhaled mRNA therapeutics. Ethris is seeking to forge strategic partnerships and licensing arrangements with companies that share our vision of advancing the development of innovative mRNA-based therapies and vaccines.